Evidence map›Paper›PMID 31515154›Full record

Trial reportThe Lancet. Oncology2019

Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.

Paul G Corn, Elisabeth I Heath, Amado Zurita, Naveen Ramesh, Lianchun Xiao, Emi Sei, Elsa Li-Ning-Tapia, Shi-Ming Tu, Sumit K Subudhi, Jennifer Wang and 7 more

Erratum issuedAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 109 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 5 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 5 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Guideline
  6. Trial
  7. Trial
  8. Trial
  9. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  10. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Paul G CornDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elisabeth I HeathDepartment of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Amado ZuritaDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naveen RameshDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lianchun XiaoDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emi SeiDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elsa Li-Ning-TapiaDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shi-Ming TuDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer WangDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xuemei WangDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eleni EfstathiouDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Timothy C ThompsonDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patricia TroncosoDepartment of Anatomical Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicholas NavinDepartment of Genetics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana M AparicioDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: aaparicio@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USThe Barbara Ann Karmanos Cancer Institute · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tumor Biology and Microenvironment (Program 1)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · PI PAUL M STEMMER · 1985 to 2026
$68.4M
Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LOGOTHETIS, CHRISTOPHER J., THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA022453NCI NIH HHS P50 CA140388
6 · The paper itself

Abstract

backgroundTaxane-platinum combinations have shown promising activity in metastatic castration-resistant prostate cancers in single-group clinical studies but not in randomised trials. Distinct biological subsets of the disease might derive the greatest benefit from the addition of platinum. We aimed to determine whether adding carboplatin to cabazitaxel would improve the outcomes of men with metastatic castration-resistant prostate cancer.

methodsWe did a phase 1-2, open label, randomised study at two centres in men with progressive metastatic castration-resistant prostate cancer. In phase 1, patients received intravenous cabazitaxel 20-25 mg/m

findingsBetween Aug 17, 2012, and May 11, 2015, nine patients completed phase 1 as planned, and 160 were randomly assigned to cabazitaxel (n=79) or cabazitaxel plus carboplatin (n=81) in phase 2. During phase I, grade 3 adverse events were anaemia (n=2), fatigue (n=1), thrombocytopenia (n=1), hypomagnesaemia (n=1), diarrhoea (n=1), hypokalaemia (n=1), anorexia (n=1), and dehydration (n=1), and no grade 4 adverse events occurred. No dose-limiting toxicities were observed, therefore, a maximum tolerated dose of cabazitaxel of 25 mg/m

interpretationCarboplatin added to cabazitaxel showed improved clinical efficacy compared with cabazitaxel alone for men with metastatic castration-resistant prostate cancer. Although adverse events were more common with the combination, the treatment was safe and generally well tolerated. Our data suggest that taxane-platinum combinations have a clinically beneficial role in advanced prostate cancer and a randomised phase 3 study is planned.

fundingSanofi Genzyme, University of Texas MD Anderson Cancer Center Prostate Cancer Moon Shot Program, and Solon Scott III Prostate Cancer Research Fund.

Indexed as

AgedAnemiaAnorexiaAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinDehydrationDiarrheaFatigueHumansHypokalemiaMaleMaximum Tolerated DoseMiddle AgedNeoplasm MetastasisNeutropeniaAntineoplastic AgentscabazitaxelCarboplatinTaxoids

Identifiers

PMID31515154
PMCPMC6858999
OpenAlexW2972985040

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.